UCB

RYSTIGGO

Manufacturer:

UCB

Rystiggo HCPCS:

J9333

HCPCS Code Descriptor:

Injection, rozanolixizumab-noli, 1 mg

Category:

J Code

Rystiggo NDCs:

50474-0980-79

Primary Type:

Immunology

Generic/Specialty Status:

Single-Source

Route of Administration:

Subcutaneous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Rystiggo:

RYSTIGGO is a Immunology drug manufactured by UCB and administered via the Subcutaneous route of administration. The J Code: J9333 is aligned to the drug RYSTIGGO.

Rystiggo is a subcutaneous injection used to treat muscle weakness in patients with generalized myasthenia gravis, a serious muscle condition. Generalized myasthenia gravis is a rare condition characterized by severe muscle weakness, which can cause breathing problems, vision problems, and difficulty swallowing, talking, and chewing. Rystiggo works by attaching to and blocking a certain receptor in the body which is responsible for regulating levels of autoantibodies. In patients with generalized myasthenia gravis, autoantibodies can prevent the muscles from contracting normally, thus leading to muscle weakness.

ACCESS PRICING AND MORE BY REGISTERING

J9333 Added Date:

January 1, 2024

J9333 Effective Date:

January 1, 2024

J9333 Termination Date:

HCPCS Active

Rystiggo billing and coding information can be found through Ucb at the link below:
Rystiggo patient assistance information can be found through The Onward Patient Support Program at the URL: https://www.rystiggo.com/cost
RYSTIGGO prescribing information can be found at the link below:
Information regarding RYSTIGGO’s side effects can be found at MedlinePlus